Legend Biotech CEO Ying Huang

#AS­CO22: Leg­end, J&J say Carvyk­ti holds up past the two-year mark as pair preps for po­ten­tial sec­ond nod

CHICA­GO — The sec­ond BC­MA CAR-T ap­proved, Carvyk­ti, has shown it can stay ef­fec­tive at al­most 28 months of me­di­an fol­low-up, with over­all re­sponse rate re­main­ing con­sis­tent at 98% among the 97 pa­tients treat­ed.

Those are the lat­est da­ta from Leg­end Biotech’s Carvyk­ti, in part­ner­ship with J&J’s Janssen, shared Sat­ur­day at the an­nu­al AS­CO meet­ing. At 28 months fol­low-up from the Phase Ib/II CAR­TI­TUDE-1 study, 70% of pa­tients were still alive and 55% ex­pe­ri­enced no pro­gres­sion in their mul­ti­ple myelo­ma. Me­di­an OS and PFS have not been reached yet.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.